Supplemental Figure 1



Supplementary Figure S1. AMG 510 demonstrates cooperativity with SHP2 and RTK inhibition.(A) SW837, SW1463, and MIA PaCa-2 $KRAS^{G12C}$ mutant cell lines were treated with AMG 510 (100 nM) alone or combined with SHP099 (10 μM) or RMC-4550 (1 μM) for 0, 4, 24, 48, and 72 h. Blot analysis was performed for pMEK, pERK, pRSK, pAKT, and total MYC with GAPDH as a loading control. (B) MIA PaCa-2 treated with a dose titration of 0.03-1 μM AMG 510 for 4 or 48 h and lysates were subject to a RAF-RBD pulldown and blot analysis of KRAS, NRAS, HRAS and total RAS as well as pERK, pRSK and GAPDH for input samples. (C) Cell lines were treated for 10-14 days AMG 510 (100 nM), SHP099 (10 μM), RMC-4550, erlotinib, afatinib, crizotinib or BGJ398 (all 1 μM) and then stained with crystal violet. (D) Individual quantification of cell lines treated in (C).